Klassen Preston
Insider CIK 1493056 · ARNA EVP and CMO · OREX SVP, Head Global Development · CNAT Director · RGLS President & Head of R & D, Director · MTCR President & CEO, Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 120,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 225,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 350,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 528,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer deriv | 2025-06-25 | 2025-06-27 | 675,000 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | D To issuer | 2025-06-25 | 2025-06-27 | 115,555 | — | $0 | 0 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | P Buy | 2025-06-03 | 2025-06-04 | 12,000 | $7.99 | $95.9K | 48,055 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2025-01-30 | 2025-01-31 | 675,000 | — | $0 | 675,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | S Sale | 2025-01-13 | 2025-01-15 | 31,445 | $1.26 | $39.6K | 36,055 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2025-01-09 | 2025-01-10 | 37,500 | $1.36 | $51.0K | 37,500 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award | 2025-01-09 | 2025-01-10 | 30,000 | $1.30 | $39.0K | 67,500 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2024-05-20 | 2024-05-21 | 528,000 | — | $0 | 528,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2024-01-12 | 2024-01-17 | 120,000 | — | $0 | 120,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2023-08-10 | 2023-08-14 | 225,000 | — | $0 | 225,000 | SEC↗ |
| RGLS Regulus Therapeutics Inc. | A Award deriv | 2023-06-12 | 2023-06-12 | 350,000 | — | $0 | 350,000 | SEC↗ |
| MTCR Metacrine, Inc. | D To issuer deriv | 2023-03-23 | 2023-03-24 | 842,211 | — | $0 | 0 | SEC↗ |
| MTCR Metacrine, Inc. | A Award | 2023-03-23 | 2023-03-24 | 842,211 | $0.47 | $395.8K | 1,384,116 | SEC↗ |
| MTCR Metacrine, Inc. | S Sale | 2023-01-26 | 2023-01-27 | 380,605 | $0.41 | $156.0K | 541,905 | SEC↗ |
| MTCR Metacrine, Inc. | S Sale | 2022-04-19 | 2022-04-20 | 1,173 | $0.51 | $598 | 922,510 | SEC↗ |
| MTCR Metacrine, Inc. | S Sale | 2022-04-19 | 2022-04-20 | 43,575 | $0.50 | $21.8K | 923,683 | SEC↗ |
| MTCR Metacrine, Inc. | A Award | 2022-04-14 | 2022-04-18 | 104,500 | — | $0 | 967,258 | SEC↗ |
| MTCR Metacrine, Inc. | A Award deriv | 2022-02-27 | 2022-03-01 | 842,211 | — | $0 | 842,211 | SEC↗ |
| MTCR Metacrine, Inc. | A Award | 2022-02-27 | 2022-03-01 | 842,211 | — | $0 | 862,758 | SEC↗ |
| MTCR Metacrine, Inc. | P Buy | 2021-05-20 | 2021-05-20 | 20,547 | $3.64 | $74.8K | 20,547 | SEC↗ |
| MTCR Metacrine, Inc. | A Award deriv | 2021-02-10 | 2021-02-12 | 247,500 | — | $0 | 247,500 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | A Award deriv | 2020-03-01 | 2020-03-03 | 70,000 | — | $0 | 70,000 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | M Exercise deriv | 2019-10-14 | 2019-10-16 | 6,300 | — | $0 | 18,900 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | F Tax w/h | 2019-10-14 | 2019-10-16 | 2,309 | $47.32 | $109.3K | 3,991 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | M Exercise | 2019-10-14 | 2019-10-16 | 6,300 | — | $0 | 6,300 | SEC↗ |
| CNAT Conatus Pharmaceuticals In | A Award deriv | 2019-06-27 | 2019-07-01 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | M Exercise deriv | 2019-01-08 | 2019-01-08 | 3,000 | — | $0 | 110,350 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | S Sale | 2019-01-08 | 2019-01-08 | 3,000 | $44.00 | $132.0K | 0 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | M Exercise | 2019-01-08 | 2019-01-08 | 3,000 | $15.10 | $45.3K | 3,000 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | M Exercise deriv | 2019-01-07 | 2019-01-08 | 16,000 | — | $0 | 113,350 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | M Exercise | 2019-01-07 | 2019-01-08 | 16,000 | $15.10 | $241.6K | 16,000 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | S Sale | 2019-01-07 | 2019-01-08 | 400 | $42.32 | $16.9K | 0 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | S Sale | 2019-01-07 | 2019-01-08 | 15,600 | $41.68 | $650.2K | 400 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | A Award deriv | 2019-01-04 | 2019-01-08 | 75,000 | — | $0 | 75,000 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | A Award deriv | 2019-01-04 | 2019-01-08 | 12,600 | — | $0 | 12,600 | SEC↗ |
| CNAT Conatus Pharmaceuticals In | A Award deriv | 2018-06-21 | 2018-06-25 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | A Award deriv | 2018-01-19 | 2018-01-22 | 130,000 | — | $0 | 130,000 | SEC↗ |
| CNAT Conatus Pharmaceuticals In | A Award deriv | 2017-06-22 | 2017-06-26 | 20,000 | — | $0 | 20,000 | SEC↗ |
| ARNA ARENA PHARMACEUTICALS INC | A Award deriv | 2017-03-20 | 2017-03-20 | 1,293,500 | — | $0 | 1,293,500 | SEC↗ |
| CNAT Conatus Pharmaceuticals In | A Award deriv | 2016-06-23 | 2016-06-24 | 20,000 | — | $0 | 20,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2016-02-02 | 2016-02-04 | 350,000 | — | $0 | 350,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2016-02-02 | 2016-02-04 | 190,000 | — | $0 | 190,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award | 2015-11-30 | 2016-02-04 | 4,170 | $2.03 | $8.5K | 10,160 | SEC↗ |
| CNAT Conatus Pharmaceuticals In | A Award deriv | 2015-06-11 | 2015-06-15 | 15,000 | — | $0 | 15,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award | 2015-05-30 | 2016-02-04 | 1,860 | $4.17 | $7.8K | 5,990 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2015-02-03 | 2015-02-05 | 182,650 | — | $0 | 182,650 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award | 2014-11-28 | 2015-02-05 | 1,542 | $4.92 | $7.6K | 4,130 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award | 2014-05-30 | 2015-02-05 | 1,318 | $5.25 | $6.9K | 2,588 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2014-02-07 | 2014-02-11 | 205,000 | — | $0 | 205,000 | SEC↗ |
| CNAT Conatus Pharmaceuticals In | A Award deriv | 2014-02-07 | 2014-02-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award | 2013-11-29 | 2014-02-11 | 1,270 | $5.34 | $6.8K | 1,270 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise deriv | 2013-07-25 | 2013-07-29 | 71,229 | — | $0 | 732,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | S Sale | 2013-07-25 | 2013-07-29 | 71,229 | $7.16 | $510.0K | 0 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise | 2013-07-25 | 2013-07-29 | 71,229 | $1.66 | $118.2K | 71,229 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise deriv | 2013-05-28 | 2013-05-30 | 28,771 | — | $0 | 803,229 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | S Sale | 2013-05-28 | 2013-05-30 | 28,771 | $7.21 | $207.4K | 0 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | M Exercise | 2013-05-28 | 2013-05-30 | 28,771 | $1.66 | $47.8K | 28,771 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2013-02-15 | 2013-02-19 | 245,000 | — | $0 | 245,000 | SEC↗ |
| OREX Orexigen Therapeutics, Inc | A Award deriv | 2012-01-25 | 2012-01-26 | 350,000 | — | $0 | 350,000 | SEC↗ |